Jeff Tyner, Ph.D, and Tyner Lab

Oregon Health & Science University provides a curated selection of high-resolution photos, video footage, b-roll and graphics for news organizations and media coverage related to OHSU stories. Commercial use is prohibited without prior written consent.

Media usage guidelines

  • Photos and video should be credited as “OHSU/Photographer name.”
  • Metadata includes captions and usage restrictions.
  • Color correction and cropping are allowed. The content or nature of the photo may not be altered.

Questions or requests: Please contact OHSU Strategic Communications at news@ohsu.edu or 503-494-8231.

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Karen Morris, Faith Burns, and Luca Sax work in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Tyner Lab 2022
Tyner Lab 2022

Images from Jeff Tyner, Ph.D., lab inside the OHSU Knight Cancer Research Building. (OHSU/Christine Torres Hicks)

Tyner Lab 2022
Tyner Lab 2022

Images from Jeff Tyner, Ph.D., lab inside the OHSU Knight Cancer Research Building. (OHSU/Christine Torres Hicks)

Knight Cancer Institute Research
Knight Cancer Institute Research

The Knight Cancer Institute is the only National Cancer Institute-designated Comprehensive Cancer Center between Sacramento and Seattle — an honor earned only by the nation's top cancer centers. It offers the latest treatments and technologies as well as hundreds of research studies and clinical trials. (OHSU/Christine Torres Hicks)

Jeff Tyner, Ph.D.
Jeff Tyner, Ph.D.

Jeffrey Tyner, Ph.D., co-led new research that zeros in on a potential drug targeted to stop acute myeloid leukemia. (OHSU/Christine Torres Hicks)

Jeff Tyner, Ph.D.
Jeff Tyner, Ph.D.

Jeffrey Tyner, Ph.D., co-led new research that zeros in on a potential drug targeted to stop acute myeloid leukemia. (OHSU/Christine Torres Hicks)